{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:12:57Z","timestamp":1793776377442,"version":"4.6.1"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"Importance<\/jats:title>\u03b2-amyloid plaques and neurofibrillary tau deposits biologically define Alzheimer disease.<\/jats:p><\/jats:sec>Objective<\/jats:title>To perform post hoc analyses of amyloid reduction after donanemab treatment and assess its association with tau pathology and clinical measures.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The Study of LY3002813 in Participants With Early Symptomatic Alzheimer\u2019s Disease (TRAILBLAZER-ALZ) was a phase 2, placebo-controlled, randomized clinical trial conducted from December 18, 2017, to December 4, 2020, with a double-blind period of up to 76 weeks and a 48-week follow-up period. The study was conducted at 56 centers in the US and Canada. Enrolled were participants from 60 to 85 years of age with gradual and progressive change in memory function for 6 months or more, early symptomatic Alzheimer disease, elevated amyloid, and intermediate tau levels.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Donanemab (an antibody specific for the N-terminal pyroglutamate \u03b2-amyloid epitope) dosing was every 4 weeks: 700 mg for the first 3 doses, then 1400 mg for up to 72 weeks. Blinded dose-reduction evaluations occurred at 24 and 52 weeks based on amyloid clearance.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Change in amyloid, tau, and clinical decline after donanemab treatment.<\/jats:p><\/jats:sec>Results<\/jats:title>The primary study randomized 272 participants (mean [SD] age, 75.2 [5.5] years; 145 female participants [53.3%]). The trial excluded 1683 of 1955 individuals screened. The rate of donanemab-induced amyloid reduction at 24 weeks was moderately correlated with the amount of baseline amyloid (Spearman correlation coefficient r<\/jats:italic>, \u22120.54; 95% CI, \u22120.66 to \u22120.39; P<\/jats:italic>\u2009&amp;lt;\u2009.001). Modeling provides a hypothesis that amyloid would not reaccumulate to the 24.1-centiloid threshold for 3.9 years (95% prediction interval, 1.9-8.3 years) after discontinuing donanemab treatment. Donanemab slowed tau accumulation in a region-dependent manner as measured using neocortical and regional standardized uptake value ratios with cerebellar gray reference region. A disease-progression model found a significant association between percentage amyloid reduction and change on the integrated Alzheimer Disease Rating Scale only in apolipoprotein E (APOE<\/jats:italic>) \u03b54 carriers (95% CI, 24%-59%; P<\/jats:italic>\u2009&amp;lt;\u2009.001).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Results of post hoc analyses for donanemab-treated participants suggest that baseline amyloid levels were directly associated with the magnitude of amyloid reduction and inversely associated with the probability of achieving complete amyloid clearance. The donanemab-induced slowing of tau was more pronounced in those with complete amyloid clearance and in brain regions identified later in the pathologic sequence. Data from other trials will be important to confirm aforementioned observations, particularly treatment response by APOE<\/jats:italic> \u03b54 status.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03367403<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2022.2793","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T15:03:01Z","timestamp":1662994981000},"page":"1015","source":"Crossref","is-referenced-by-count":216,"title":["Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes"],"prefix":"10.1001","volume":"79","author":[{"given":"Sergey","family":"Shcherbinin","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia D.","family":"Evans","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"},{"name":"Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pontecorvo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"},{"name":"Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Willis","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"},{"name":"Now with Eisai Inc, Nutley, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivelina","family":"Gueorguieva","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Hauck","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn A.","family":"Brooks","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Mintun","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"},{"name":"Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Sims","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"noi220052r1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.14283\/jpad.2021.56","article-title":"Donanemab (LY3002813) phase 1b study in Alzheimer\u2019s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging.","volume":"8","author":"Lowe","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"issue":"18","key":"noi220052r2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease.","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"noi220052r3","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.v7.1","article-title":"Donanemab (LY3002813) dose-escalation study in Alzheimer\u2019s disease.","volume":"7","author":"Lowe","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"issue":"12","key":"noi220052r4","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","article-title":"Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the centiloid scale.","volume":"14","author":"Navitsky","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"9","key":"noi220052r5","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.2967\/jnumed.120.258962","article-title":"TauIQ\u2014a canonical image-based algorithm to quantify tau PET scans.","volume":"62","author":"Whittington","year":"2021","journal-title":"J Nucl Med"},{"issue":"7","key":"noi220052r6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F] flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes.","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol"},{"issue":"6","key":"noi220052r7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.117.200691","article-title":"Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18.","volume":"59","author":"Devous","year":"2018","journal-title":"J Nucl Med"},{"issue":"6","key":"noi220052r8","doi-asserted-by":"publisher","first-page":"944","DOI":"10.2967\/jnumed.117.200006","article-title":"Flortaucipir F 18 quantitation using parametric estimation of reference signal intensity.","volume":"59","author":"Southekal","year":"2018","journal-title":"J Nucl Med"},{"issue":"2","key":"noi220052r9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","article-title":"Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology.","volume":"15","author":"La Joie","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi220052r10","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/brain\/aww334","article-title":"Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age, and cognition.","volume":"140","author":"Pontecorvo","year":"2017","journal-title":"Brain"},{"key":"noi220052r11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.dadm.2018.01.006","article-title":"Topographic staging of tau positron emission tomography images.","volume":"10","author":"Schwarz","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"issue":"9","key":"noi220052r12","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1093\/brain\/awab114","article-title":"Early stages of tau pathology and its associations with functional connectivity, atrophy and memory.","volume":"144","author":"Berron","year":"2021","journal-title":"Brain"},{"issue":"Pt 9","key":"noi220052r13","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1093\/brain\/awu176","article-title":"A data-driven model of biomarker changes in sporadic Alzheimer\u2019s disease.","volume":"137","author":"Young","year":"2014","journal-title":"Brain"},{"issue":"4","key":"noi220052r15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.14283\/jpad.2015.82","article-title":"A combined measure of cognition and function for clinical trials: the integrated Alzheimer\u2019s Disease Rating Scale (iADRS).","volume":"2","author":"Wessels","year":"2015","journal-title":"J Prev Alzheimers Dis"},{"key":"noi220052r16","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope\u2014the Alzheimer\u2019s Disease Cooperative Study.","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"noi220052r17","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer\u2019s disease\u2014the Alzheimer\u2019s Disease Cooperative Study.","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"6","key":"noi220052r18","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1080\/10543406.2017.1315819","article-title":"Statistical properties of continuous composite scales and implications for drug development.","volume":"27","author":"Liu-Seifert","year":"2017","journal-title":"J Biopharm Stat"},{"issue":"1","key":"noi220052r19","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.v8.1","article-title":"Integrated Alzheimer\u2019s Disease Rating Scale: clinically meaningful change estimates.","volume":"8","author":"Wessels","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"noi220052r20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease.","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"noi220052r21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials.","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol"},{"issue":"6","key":"noi220052r22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10928-014-9375-z","article-title":"An updated Alzheimer\u2019s disease progression model: incorporating nonlinearity, beta regression, and a third-level random effect in NONMEM.","volume":"41","author":"Conrado","year":"2014","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"noi220052r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v048.i02","article-title":"lavaan: An R package for structural equation modeling.","volume":"48","author":"Rosseel","year":"2012","journal-title":"J Stat Softw"},{"issue":"9","key":"noi220052r24","doi-asserted-by":"publisher","first-page":"e1347","DOI":"10.1212\/WNL.0000000000011524","article-title":"Temporal dynamics of \u00df-amyloid accumulation in aging and Alzheimer disease.","volume":"96","author":"Jagust","year":"2021","journal-title":"Neurology"},{"issue":"12","key":"noi220052r25","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awx243","article-title":"Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer disease.","volume":"140","author":"Bejanin","year":"2017","journal-title":"Brain"},{"issue":"8","key":"noi220052r26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","article-title":"Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging.","volume":"78","author":"Ossenkoppele","year":"2021","journal-title":"JAMA Neurol"},{"issue":"4","key":"noi220052r27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/jamaneurol.2020.5505","article-title":"Aggregated tau measured by visual interpretation of flortaucipir positron emission tomography and the associated risk of clinical progression of mild cognitive impairment and Alzheimer disease: results from 2 phase III clinical trials.","volume":"78","author":"Lu","year":"2021","journal-title":"JAMA Neurol"},{"issue":"6","key":"noi220052r28","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/brain\/awz090","article-title":"A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment, and Alzheimer disease dementia.","volume":"142","author":"Pontecorvo","year":"2019","journal-title":"Brain"},{"issue":"1","key":"noi220052r29","first-page":"S22","article-title":"Flortaucipir in the TRAILBLAZER-ALZ trial.","volume":"8","author":"Shcherbinin","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"noi220052r14","author":"Gueorguieva","year":"2022"},{"key":"noi220052r30","unstructured":"A follow-on study of donanemab (LY3002813) with video assessments in participants with Alzheimer\u2019s disease (TRAILBLAZER-EXT). Updated May 26, 2022. Accessed August 10, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04640077"},{"key":"noi220052r31","unstructured":"A study of donanemab (LY3002813) in participants with early Alzheimer\u2019s disease (TRAILBLAZER-ALZ2). Updated August 4, 2022. Accessed August 10, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04437511"},{"key":"noi220052r32","unstructured":"A study of donanemab (LY3002813) compared with aducanumab in participants with early symptomatic Alzheimer\u2019s disease (TRAILBLAZER-ALZ4). Updated August 9, 2022. Accessed August 10, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05108922"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2795844\/jamaneurology_shcherbinin_2022_oi_220052_1665773650.66141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T15:00:36Z","timestamp":1666018836000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2795844"}},"subtitle":["The TRAILBLAZER-ALZ Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2022.2793","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}